- Home
- CRVS vs RYAM Comparison
CRVS vs RYAM Comparison
Compare CRVS & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- RYAM
- Stock Information
- Founded
- CRVS 2014
- RYAM 1926
- Country
- CRVS United States
- RYAM United States
- Employees
- CRVS N/A
- RYAM N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- RYAM Paper
- Sector
- CRVS Health Care
- RYAM Basic Materials
- Exchange
- CRVS Nasdaq
- RYAM Nasdaq
- Market Cap
- CRVS 516.0M
- RYAM 495.7M
- IPO Year
- CRVS 2016
- RYAM N/A
- Fundamental
- Price
- CRVS $5.22
- RYAM $7.88
- Analyst Decision
- CRVS Strong Buy
- RYAM Buy
- Analyst Count
- CRVS 5
- RYAM 1
- Target Price
- CRVS $12.38
- RYAM $12.00
- AVG Volume (30 Days)
- CRVS 1.6M
- RYAM 498.7K
- Earning Date
- CRVS 11-12-2024
- RYAM 02-25-2025
- Dividend Yield
- CRVS N/A
- RYAM N/A
- EPS Growth
- CRVS N/A
- RYAM N/A
- EPS
- CRVS N/A
- RYAM N/A
- Revenue
- CRVS N/A
- RYAM $1,630,290,000.00
- Revenue This Year
- CRVS N/A
- RYAM $0.95
- Revenue Next Year
- CRVS N/A
- RYAM $4.10
- P/E Ratio
- CRVS N/A
- RYAM N/A
- Revenue Growth
- CRVS N/A
- RYAM N/A
- 52 Week Low
- CRVS $1.30
- RYAM $3.15
- 52 Week High
- CRVS $10.00
- RYAM $10.28
- Technical
- Relative Strength Index (RSI)
- CRVS 41.23
- RYAM 49.89
- Support Level
- CRVS $4.60
- RYAM $7.30
- Resistance Level
- CRVS $6.47
- RYAM $7.89
- Average True Range (ATR)
- CRVS 0.39
- RYAM 0.34
- MACD
- CRVS 0.06
- RYAM 0.02
- Stochastic Oscillator
- CRVS 33.16
- RYAM 48.33
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About RYAM Rayonier Advanced Materials Inc.
Rayonier Advanced Materials Inc manufactures high-purity cellulose derived from wood. Also known as cellulose specialties, the company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, High-Yield Pulp, and Corporate and Other. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of revenue from the United States.